Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.73 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.68 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.68 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.68 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.64 |
| ▸ | TAS2R31 | P59538 | 1/20 | 0.64 |
| ▸ | FLT3 | P36888 | 2/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.60 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.60 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.60 |
| ▸ | PTGES | O14684 | 1/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10001087 | 0.93 | CYP1B1 (0.70) | HDAC6CYP1B1CYP1A1CYP1A2OPRD1 | |
| SCHEMBL10001093 | 0.93 | HSD17B2 (0.73) | HDAC6CYP1B1CYP1A1CYP1A2OPRD1 | |
| SCHEMBL10001095 | 0.90 | CYP1B1 (0.67) | HDAC6CYP1B1CYP1A1CYP1A2OPRD1 | |
| SCHEMBL10001099 | 0.90 | HDAC6 (0.72) | HDAC6CYP1B1CYP1A1CYP1A2OPRD1 | |
| SCHEMBL10001096 | 0.86 | FLT3 (0.72) | CYP1B1CYP1A1CYP1A2OPRD1FLT3 | |
| SCHEMBL10001100 | 0.85 | CYP1B1 (0.69) | HDAC6CYP1B1CYP1A1CYP1A2OPRD1 | |
| SCHEMBL16088300 | 0.85 | HDAC6 (0.78) | HDAC6CYP1B1CYP1A1CYP1A2OPRD1 | |
| Eupatilin SCHEMBL29568655 | 0.85 | HDAC6 (1.00) | HDAC6CYP1B1CYP1A1CYP1A2OPRD1 | |
| Eupatilin SCHEMBL1033509 | 0.85 | HDAC6 (1.00) | HDAC6CYP1B1CYP1A1CYP1A2OPRD1 | |
| Eupatilin SCHEMBL29926197 | 0.85 | HDAC6 (1.00) | HDAC6CYP1B1CYP1A1CYP1A2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11690841-B2 | Glycolysis-activating agents for treatment or prevention of disease | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2023-07-04 | — | — | US | disclosed |
| US-20170239211-A1 | USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY | OSTEONEUROGEN INC. (KR) | 2017-08-24 | — | — | US | disclosed |
| US-20170056367-A1 | PHARMACEUTICAL COMPOSITIONS FOR INHIBITING THE OSTEOCLAST DIFFERENTIATION COMPRISING EUPATILIN | OsteoNeuroGen CO., LTD (KR) | 2017-03-02 | — | — | US | disclosed |
| US-9301943-B2 | Use of eupatilin | UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY (KR) | 2016-04-05 | — | — | US | disclosed |
| US-20140288168-A1 | NOVEL USE OF EUPATILIN | UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY (KR) | 2014-09-25 | — | — | US | disclosed |
| US-20120029066-A1 | USE OF FLAVONES FOR TREATING PSYCHIATRIC DISORDERS WITH SENSORIMOTOR GATING DEFICITS | TAIPEI MEDICAL UNIVERSITY (TW) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288168-A1 | NOVEL USE OF EUPATILIN | ERLIN1, ERLIN2, GPR119 | HDAC6 2136/4885CYP1B1 2049/4885CYP1A1 3111/4885 |
| US-11690841-B2 | Glycolysis-activating agents for treatment or prevention of disease | HK2, PDK1, HK1 | HDAC6 702/4885CYP1B1 4295/4885CYP1A1 4046/4885 |
| US-20170056367-A1 | PHARMACEUTICAL COMPOSITIONS FOR INHIBITING THE OSTEOCLAST DIFFERENTIATION COMPRISING EUPATILIN | MYADM, CD14, ALPG | HDAC6 3638/4885CYP1B1 3753/4885CYP1A1 4078/4885 |
| US-20170239211-A1 | USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY | CDH1, SMAD3, SMAD2 | HDAC6 1189/4885CYP1B1 1004/4885CYP1A1 1456/4885 |
| US-20120029066-A1 | USE OF FLAVONES FOR TREATING PSYCHIATRIC DISORDERS WITH SENSORIMOTOR GATING DEFICITS | HTR2C, GRIN2C, HTR5A | HDAC6 4158/4885CYP1B1 1037/4885CYP1A1 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.